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1. Introduction 
Chordoma is an uncommon neoplasm of the bone arising from embryonic remnants of the 
notochord. The overall age-adjusted incidence is about 8 per 10 million, but this figure is 
dependent on age, sex, and race (Jemal et al., 2007). This tumor typically occurs in the axial 
skeleton mainly involving the sacrococcygeal region and the base of the skull (Mirra et al., 
2002). The natural history of such malignancy is of a slow but progressive growth ultimately 
translating into a local aggressive behaviour. Overall, five-year survival rates are near 60% 
to 70%, although 10-year survival drops to 35% to 40% (Dorfman, 1998). The rate of distant 
metastases (to lung, bone, soft tissue, lymph nodes, liver, and skin) varies in a range 
between 0% and 40% (Chambers et al., 1979) even though usually late detected with most 
patients succumbing to their local disease. Based on these considerations the control of 
primary disease remains the major therapeutic challenge. 
Given the rarity of this tumor, data on efficacy and safety of the treatments are limited and 
mainly based on few, small sized, retrospective series. The standard of care is considered 
surgery, when feasible, with the aim of establishing a definitive diagnosis and obtaining the 
maximal debulking of the lesion. Surgical outcomes depend on tumor location and size at 
diagnosis. Considering the large size of most sacral lesions and the proximity to critical 
healthy structures of skull base and vertebral chordomas, maximal resection usually entails 
a relevant morbidity with poor functional outcome in a significant proportion of patients. 
Therefore, even if local control and survival rates strictly depend on the achievement of 
negative margins, radical surgery can be rarely obtained (Cotler et al., 1983). In such 
scenario recurrence rates can approach 70%.  
This situation clearly supports the interest for radiation therapy as an adjuvant modality 
after residual disease even though the irregular and infiltrative nature of this tumor makes it 
difficult to be targeted. 
The role of irradiation either as a postoperative treatment or as a curative measure in 
inoperable lesions is widely debated. Chordomas have been historically considered radio 
resistant tumors requiring high doses of radiation (> 60 Gy) to respond best. However, a 
dose–response relationship has not been clearly reported across all series (Tai et al., 1995) 
and the doses needed to control the tumor in general exceed the tolerance dose levels of 
nearby normal structures (Pai, 2001; Slater, 1988). 
Several irradiation modalities have been proposed (particle therapy, intensity-modulated 
radiation therapy, stereotactic irradiation) without a clearly established superiority of one 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
92
technique over the others. No randomized studies are reported in the literature on this topic 
and the current available evidence is based on mono-institutional series using different 
treatment techniques over a long period of time, thus limiting the strength of the 
corresponding findings. 
Technological progress has made it possible to improve the quality of irradiation in an 
attempt to safely deliver high doses to the target volume while sparing organs at risk. 
Since the seventies, particles (administered either alone or in combination with conventional 
photon beam therapy) have been used with the aim to improve the clinical results. Thank to 
the rapid dose fall-off beyond the target and the corresponding sparing of surrounding 
tissues, proton beam irradiation shows a distinct dosimetric advantage over conventional 
external beam radiotherapy. Ions can exploit the same physical advantage along with a 
superior radiobiological effect.  
At the same time, the recent development of new radiation delivery modalities (such as 
intensity-modulated radiation therapy) has improved the use of conventional photon 
radiotherapy. Stereotactic radiosurgery has been used as an effective adjunct in the 
management of small tumors. Fractionated stereotactic radiotherapy with the use of micro-
multileaf collimators may help to optimize radiation delivery. As a consequence, hadron-
based radiation therapy and best photon-based techniques deserve comparative evaluations.   
To date, current data suggests that the optimal treatment strategy includes maximal safe 
resection and shaping of residual disease to a very limited volume (if any) in order to 
optimize postoperative proton or modern external photon beam radiation therapy 
(Crockard et al., 2001). 
The purpose of this chapter is to review the literature and the developments in the 
multimodal approach to chordoma with particular regard to the role of radiation therapy. 
2. Chordoma of the base of the skull 
Base of the skull presentation represents about one third of all chordomas. This tumor 
usually affects younger individuals, even children and adolescents (Tai et al., 2002), and is 
diagnosed more frequently in males. In adults, skull base chordomas occur close to the 
spheno-occipital area while craniocervical lesions most often involve dorsum sella, clivus, 
and nasopharynx. Chordoma is the only tumor that can present with dysfunction of any 
cranial nerve due to its location. Patients with skull base chordomas can also develop 
endocrinological dysfunction due to involvement of the pituitary gland within the sella 
turcica. 
The standard treatment is surgery with the aim to assess the pathological diagnosis and to 
perform the maximal resection even though a radical removal of the lesion is infrequent due 
to the critical location and the infiltrative pattern of these lesions. Gross total resection is 
accomplished in three quarter of the patients and 10-year recurrence free survival is about 
30% (Tzorzidis et al., 2006). As a consequence, the likelihood of tumor control is low after 
surgery alone, even after gross total removal (Menezes et al., 1997). For this reasons, in an 
attempt to accomplish radical resection and improve the overall outcome, advanced 
microsurgical techniques have been developed and applied into skull base surgery (Scholz 
et al., 2010). However, the possibility of complete resection, even with modern surgical 
techniques, has been associated with still high morbidity and mortality rates (Monfared et 
al., 2007) as well as with the risk of permanent neurological deficits in 25% of patients (Gay 
et al., 1995).  
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The tumor can keep stable even after subtotal resection but the patients ultimately 
experience local recurrence and need to repeat surgery during the course of their disease. 
Moreover, recurrent tumors are generally more challenging for surgical interventions and 
have worse overall outcomes. 
In order to avoid the potential evolution of the residual disease, the use of conventional 
photon radiotherapy was introduced in the eighties in the postoperative setting without 
being able to increase survival rates but showing longer local control in comparison to 
surgery alone (Table 1). 
 
Author Year Pts 
TD range 
in Gy 
(med) 
% OS 
(years) 
 
5           10 
% LC 
(years) 
 
5           10 
Med 
F/U in 
months 
Cummings et al. 1983 10 25-60 (50) 62          28 41 (3.5) 40 
Chetiyawardana 
et al. 
1984 14 30-40 45          23 NA 12-240 
Raffel et al. 1985 17 
36-69.36 
(54.54) 
70           -- 47           -- 60 
Amendola et al. 1986 11 
53.2-66.3 
(60) 
30           -- 40 (3) 48 
Fuller & Bloom 1986 13 47-65 (55) 44          17 23          16 31 
Forsyth et al. 1993 39 
22.93-67.42 
(50) 
51          35 39          31 99 
Watkins et al. 1993 38 50-60 63          59 34           -- 84 
Catton et al. 1996 20 25-60 (50) 54          20 23          15 62 
Zorlu et al. 2000 18 50-64 (60) 35           -- 23           -- 42 
Cho et al. 2008 11 
50.4-69.3 
(59.4) 
72           -- 40           -- 55 
Legend: Pts: patients; Gy: Gray; TD: total dose; NA: not available; OS: overall survival; LC: local control; 
Med: median; F/U: follow-up. 
Table 1. Published studies on photon beam conventional radiation therapy of skull base 
chordoma 
In general, the series using conventional radiotherapy report on a limited number of 
patients, treated with median total doses between 50 and 60 Gy, far from the needed high 
dose level to control such a tumor. As a consequence, the rates of long-term response and 
survival resulted limited. 
High doses (in the range of 70-75 Gy) of radiation are considered necessary for treating 
chordoma, but, unfortunately, nearby critical neurologic structures (spinal cord, brainstem, 
optic nerves and chiasm) limit the doses that can be delivered with conventional techniques.  
Charged particles, alone or in combination with photons, have been used since long time 
after surgical excision providing adequate support to their use for their peculiar 
physical/dosimetric advantage (protons and ions) and radiobiological features (ions) over 
conventional photon radiotherapy. The estimated overall survival rates obtained with 
protons range between 62% and 80.5% at 5 years and are of 54% at 10 years (see Table 2). 
Several types of ions (Helium, Neon, Carbon) have been also used with comparable results 
(see Table 3).  
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Author Pts 
Rad. 
type 
TD in 
CGE 
(range) 
% LC 
at 5 years 
% OS 
at 5 years 
Med 
F/U 
in 
months 
Hug et al. 33 P 
71.9 
(66.6-79.2) 
59 79 33.2 
Munzenrid
er & 
Liebsch 
169 P + Ph 
66-83 
 
73 
(10-year: 54) 
80 
(10-year: 54) 
41 
Igaki et al. 13 P 
72 
(63-95) 
46 66.7 69.3 
Weber et al. 18 P 
74 
(67-74) 
87.5 
(3-year) 
93.8 
(3-year) 
 
29 
Noël et al. 100 P + Ph 
67 
(60-71) 
53.8 
(4-year) 
80.5 
31 
 
Ares et al. 42 
P (+Ph 4 
pts) 
73.5 
(67-74) 
81 62 38 
Legend: Pts: patients; Rad.: radiation; P: protons; Ph: photons; LC: local control; OS: overall survival; 
Med: median; F/U: follow-up; TD: Total dose; CGE: Cobalt Gray equivalent. 
Table 2. Series of skull base chordoma treated with protons 
 
Author Pts 
TD in 
CGE 
% LC 
at 5 years 
% OS 
at 5 years 
Med F/U 
in months 
Berson et al. 32 59.4-80 
classical Ch 55, 
chondroid Ch 36
classical Ch 89, 
chondroid Ch 80
min. 12 
 
Castro et al. 53 
60-80 
(mean 
65) 
63 75 51 
Schulz-
Ertner et al. 
96 
60-70 
(med 60) 
70 88.5 31 
Tsujii et al. 25 48-60.8 
88 
(3-year) 
86 NA 
Mizoe et al. 34 48-60.8 85.1 87.7 53 
Legend: Pts: patients; LC: local control; OS: overall survival; med: median; F/U: follow-up; TD: total 
dose; NA: not available; CGE: Cobalt Gray equivalent; Ch: chordoma; min: minimum. 
Table 3. Series of skull base chordoma treated with ions 
The debate on the use of this wide set of irradiation techniques is still open in the radiation 
therapy community (Brada, 2007, Lodge, 2007, Goitein, 2008). Proton therapy is now widely 
considered the best radiotherapeutic approach but high level of evidence is still lacking. 
Hence, this treatment modality probably deserves comparative evaluations with the other 
available conformal technologies in order to optimize the management of the patients, 
tailoring the radiation treatment to each specific clinical presentation. 
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From this standpoint, newer methods of delivering photon-based radiation therapy, 
including fractionated stereotactic radiation therapy, radiosurgery and intensity-modulated 
radiation therapy have allowed to deliver the dose with better conformity. In particular, 
despite the limitation concerning the small size of the suitable target, gamma-knife surgery 
is the most frequently used radiosurgical machine and it has been employed also in the 
treatment of skull base chordomas. However, data of the most recent literature on this 
argument (see Table 4) show not consistent results in terms of local control.  
 
Author Pts 
Mean 
treated 
volume 
Type of 
radiation 
treatment 
Med 
dose in 
Gy 
% LC 
(years) 
 
5        10 
% OS 
(years) 
 
5        10 
Med 
F/U in 
months 
Chang et 
al. 
10 1.1-21.5 mL 
5 CyberK, 
5 LINAC 
19.4 2 PD NA 4 
Crockar
d et al. 
26 
40.8 cm3 
(pre-op.) 
GK 15 NA 65           - 51 
Krishnan 
et al. 
25 14.4 cm3 
GK 
 
15 
32         - 
 
88          - 56 
Martin et 
al. 
18 
9.8 cm3  
(average) 
GK 16.5 
63         - 
(+ 10.4) 
63          - 88 
Hasegaw
a et al. 
30 19.7 mL 
GK 
 
14 .0 
72      67 
 
 
80         56 59 
Kano et 
al. 
71 7.1 cm3 GK 15.0 66         - 80           - 60 
Legend: Pts: patients; NA: not available; Gy: Gray; LC: local control; med: median; F/U: follow-up; pre-
op.: preoperative; GK: gamma knife; CyberK: cyberknife; LC: local control; OS: overall survival; PD: 
progression disease. 
Table 4. Data of patients with base of the skull chordoma treated with radiosurgery  
2.1 Pediatric chordoma 
The median age at presentation of chordomas is around 60 years; however, such skull base 
tumors may occur also at a younger age and has been reported in children and adolescents 
(Tai et al., 1995). 
Special techniques such as intensity-modulated radiation therapy, brachitherapy or 
intraoperative radiotherapy have been introduced in the management of childhood tumors 
(Saran, 2004). Proton therapy is treating an increasing proportion of patients (DeLaney et al., 
2005) and there is a general agreement that protons will play a major role in the future in 
treating childhood cancer (Wilson et al., 2005) for its peculiar properties in the potential 
reduction of secondary cancer risk and reducing rates of late side effects (Miralbell, 2002; 
Schneider, 2008). Table 5 summarizes some data on the use of particle therapy in chordoma 
presenting during childhood. In general it is possible to observe that patients with cervical 
chordoma had a significant worse survival than those with base of the skull presentation, 
that survival in males was significant superior than in females, and that the reported rate of 
Grade 3-4 late side effects is very low. 
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Author Pts Radiation TD in CGE 
% LC 
at 5 years 
% OS 
at 5 years 
Med F/U 
in months 
Hug et al 10 P 
73.7 
(70-78.6) 
60 60 30 
Hoch et al. 73 P NA NA 81 86.5 
Habrand et al. 26 P + Ph 69.1 77 100 26.5 
Rombi et al. 19 P 
74.0 
(73.8-75.6) 
81 89 46 
Combs et al. 7 I 60-66.6 1 progression - 49 
Legend: Pts: patients; P: protons; Ph: photons; I: ions; CGE: Cobalt Gray equivalent; LC: local control; 
OS: overall survival; med: median; F/U: follow-up; TD: Total dose; NA: not available. 
Table 5. Series of skull base pediatric chordoma treated with particles 
3. Chordoma of the spinal axis 
Overall, chordoma of the spine represents more than half of all chordomas. Along the spinal 
axis, the most common site of origin is the sacrococcygeal region. The distribution of  
the remaining vertebral group, in a decreasing order of frequency, is cervical, lumbar  
and thoracic, respectively. Bjornsson et al. did report that 325 chordomas were diagnosed  
at the Mayo Clinic since 1902 (Bjornsson et al., 1993). One hundred fifty-six patients (48%) 
had tumors involving the sacrococcygeal region and 44 (13.5%) had chordomas of the 
mobile spine. 
Because of their slow growth rate, the onset of symptomatology is gradual and long lasting 
with early symptoms differing according to the anatomical location. At the time of 
diagnosis, most patients experience pain secondary to bone destruction. However, sacral 
chordomas may cause rectal and urinary dysfunctions as well as deficient motor function of 
the lower extremities, whereas lesions involving the rest of the spine usually compress the 
nerve roots, the spinal cord or adjacent organs mainly translating into sensory deficits, 
motor disturbances or organ-specific symptoms. 
The above-mentioned variability according to the anatomical localization of the tumor  
along the spinal axis also concerns the tumor size at diagnosis. In fact, sacrococcygeal 
chordomas can grow filling up the pelvic spaces so that they are usually huge, whereas the 
limited space availability along the mobile spine translate into an earlier diagnosis  
of smaller lesions. 
The treatment mostly advocated in the literature is surgery. However, the impossibility  
to achieve an oncologically adequate tumor resection at least in a certain amount of 
patients has increased the use of radiation therapy as well. Unfortunately, because of the 
low incidence rate of this malignancy only few centers have achieved extensive 
experience in the management of chordomas. Nevertheless, the relative rarity of 
chordomas also explains why the patients collected in clinical series were treated over a 
long period of time and even managed according to different strategies. Overall, such 
drawbacks hampered the attainment of robust evidence able to lead the therapeutic 
strategies. 
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The present section addresses the main issues dealing with each treatment modality and 
provides an overview of the main clinical series reported in the literature. 
3.1 Surgical management 
The spine has a very complex anatomy due to its relationship with vessels (e.g. vertebral 
arteries in the cervical region), joints, nerve roots, and nearby organs. Besides, structural 
peculiarities featuring each spinal segment itself add further difficulty. Overall, this makes it 
tough to accomplish an oncologically proper tumor resection and increases the surgical 
morbidity as well as mortality. Hence, the best surgical care must include an experienced 
multidisciplinary team with an oncologic orthopedist, a spine surgeon, a plastic one and a 
vascular surgeon as well. In fact, several authors noted that patients who received their 
original surgical procedures outside of recognized centres had worse local control (Bergh, 
2000, Schwab, 2009) and/or overall survival (Choi et al., 2010), emphasizing the critical role 
of experience and clinical expertise in managing this rare malignancy. 
Early studies on spinal chordomas reported that the very high local recurrence rates 
following conventional surgical debulking entailed a very poor survival (Eriksson et al., 
1981). Clinical outcomes are considerably improved by the means of better surgical 
techniques that allowed wide resections and complete removal of the tumors (Boriani et al., 
2009). From this standpoint, several series with long enough follow-up have demonstrated 
that radical resection with adequate surgical margins translates into high local control rate, 
which ultimately prolongs overall survival. So far, patients amenable by wide resection with 
adequate margins range between 23% (Yonemoto et al., 1999) and 82% (Ozger et al., 2010) 
mainly depending on tumor location along the spine and size of the lesion. In fact, the 
number of vertebral chordomas suitable for radical resection is usually smaller than that 
occurring in the sacrococcygeal area (Sundaresan, 1979, Bjornsson, 1993, Boriani, 2006). 
Accomplishing this type of surgery contributes to high absolute local control rates that are 
very consistent and vary mainly between 72% (Kaiser et al., 1984) and 87% (Hsieh et al., 
2009). Few series pointed out even the absence of local relapse (Yonemoto, 1999, Osaka, 
2006). Concerning overall survival, radical resection can achieve absolute values in the range 
of even 90-100% even though these values are reported by a very limited number of studies 
(Hsieh, 2009, Fuchs 2005). It is noteworthy, that while in some series inadequate surgical 
margins were an adverse prognostic factor for local recurrence (York, 1999, Bergh, 2000) or 
for both local recurrence and overall survival (Fuchs et al., 2005), other authors pointed out 
the lack of such a role (Hulen, 2006, Schwab, 2009). However, ensuring adequate margins 
can be at the expense of relevant surgical morbidity and mortality. In the management of 
vertebral chordomas, neurologic deficit and early postoperative deaths have been reported 
till 55% (Bergh et al., 2000) and 12% of the patients respectively (Boriani et al., 2006). In 
sacrococcygeal surgical procedures, neurologic deficit correlate with the number of 
sacrificed nerve roots and the rate of bowel, bladder and sexual dysfunctions can score 89%, 
74% and 67%, respectively (Schwab et al., 2009). Besides, fatigues fractures can occur up to 
20% of the patients (Bergh et al., 2000), ambulatory deficits till 10% (Hsieh et al., 2009) and 
wound complications up to 50% of the cases (Hulen et al., 2006) while mortality can achieve 
18% (Ozger et al., 2010). 
Finally, it is proper to remark that despite apparently macroscopic total resection, local 
recurrence of disease is not a rare event with most series reporting a rate between 20% 
(Boriani et al., 2006) and 29% (Ozgeret al., 2010). 
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3.2 Radiotherapy 
Local recurrence and progression are inevitable in case of suboptimal surgery. Hence, 
postoperative adjuvant radiotherapy has been widely employed in the attempt to achieve 
local control and possibly improving overall survival. 
Since the seventies radiotherapy has been applied both as a curative and adjuvant treatment of 
spinal chordomas. However, for tumors in this location, it is to note that radiation oncologists 
face the same constraints hampering an adequate surgical excision. In fact, the tolerance dose 
of most organs nearby the spine is widely below that providing effective treatment. 
From this standpoint, it is not surprising that most of the series employing photon 
radiotherapy (the main series are reported in Table 6) were not able to deliver average doses 
exceeding 60 Gy. However, the most recent studies pointed out that the evolutionary 
developments of photon techniques such as three-dimensional conformal radiation therapy 
and intensity-modulated radiation therapy allowed the delivery of more than 70 Gy though 
employed only in a limited number of patients. 
 
Author 
N. Irr. 
Pts 
Site Surg 
Dose in Gy 
Mean/Range
Results (%)
Med 
F/U in 
months 
(range) 
Conventional photon radiotherapy
Cummings 
et al. 
11 11 S 
2 ST, 
9 B 
48/24-66 
OS
5y 62 
10y 28
NR 
O’Neill 
et al. 
11 11 S-Cx 
3 MT, 
8 ST 
-/10-60 
ST+RT°
5y OS 55 
10y OS 20
(12-240) 
Fuller & Bloom 12 9 S, 3 SP
5 ST, 
7 B 
52/30-70 
LC°
5y 42 
10y 0 
OS° 
5y 50 
10y 0
Min 60 
Romero 
et al. 
10 
5 S-Cx, 
5 SP 
8 ST, 
2 B 
Conv
60/56-65 
Hyper 
40/30-59
5y PFS° 0 
5y OS° 20 
Mean 54 (12-
102) 
Samson 
et al. 
16 21 S NR -/50-65 
LC°
5y 77 
10y 77
Mean 54 
Cheng 
et al. 
13 13 S-SP 13 M/I 54/40-70 
LC°
5y 72 
10y 44 
OS° 
5y 84 
10y 43
Mean 84 (18-
288) 
York 
et al. 
18 18 S 
8 MT, 
10 ST 
53/30-74 
ST+RT
Med TtR 25 
months
43 
(4-408) 
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Baratti 
et al. 
10 10 S-Cx 10 M/I -/50-60 Ab. LC 50 
71 
(15-200) 
Atalar 
et al. 
10 10 S-Cx 
7 M/I, 
3 B
52/50-62 
3y LC° 60
3y OS° 78
Mean 65 
(7-152) 
Boriani 
et al. 
34 34 SP 
8 E-b I/C, 
16 I, 
10 B/P 
40-44/- 
I surg +RT
Ab LC 25 
E-b surg 
+RT 
Ab LC 50
(3-155) 
Stacchiotti 
et al. 
42 42 S-SP 
4 W, 
13 M, 
25 I 
79% pts <60 
Gy 
21% pts ≥60 
Gy 
LC
5y 52 
10y 33 
OS 
5y 85 
10y 58
142 
(76-210) 
Chen 
et al. 
15 15 S 15 M/I 50/30-60 
Cont. DFS
5y 59 
10y 42
Mean 74 
(16-182) 
“High-tech” photon radiotherapy
Zabel-du Bois 
et al. 
34 34 S 
4 R0,
4 R1, 
16 R2, 
10 B
PTV1
-/40-66 
PTV2 
-/60-72
5y LC 27 
5y OS 70 
54 
(4-109) 
Legend: N.: number; irr.: irradiated; pts: patients; surg.: surgery; Gy: Gray; med: median; F/U: follow-
up; S: sacral; Cx: coccygeal; SP: spinal; MT: macroscopically total resection; ST: subtotal resection; B: 
biopsy; M: marginal; I: intralesional; W: wide; C: contamined; P: palliative; E-b: en bloc; R0: complete 
resection; R1: microscopic residual tumor; R2: macroscopic residual tumor; conv: conventional 
fractionation; hyper: hyperfractionated regimen; PTV: planning target volume; RT: adjuvant 
radiotherapy; OS: overall survival; LC: local control; y: year; TtR: time to recurrence; ab.: absolute; cont.: 
continuous; DFS: disease-free survival; °: data from article’s graphics; NR: not reported; min: minimum. 
Table 6. Main series concerning vertebral chordomas treated with photon radiotherapy 
The analysis of the results dealing with photon radiotherapy shows that there was a great 
variability among the radiation regimens in terms of both total dose and dose per fraction. 
Probably, this feature can explain why data are not consistent. Overall, the use of a 
postoperative dose usually less than 60 Gy improved local control compared to subtotal 
resection only (Cummings, 1983, O’Neill, 1985, Fuller, 1988, Romero, 1993). However, such a 
dose level does not provide long lasting results. The resulting 5-year local control is only 
42% (Fuller & Bloom, 1988) and 10-year overall survival ranges between 0% (Fuller & 
Bloom, 1988) and 28% (Cummings et al., 1983). At the same time, there are also some series 
providing better results. Probably, this is because these studies delivered a slightly higher 
dose to most patients. The corresponding 5-year local control varied between 50% (Baratti et 
al., 2003) and 77% (Samson et al., 1993) while 10-year overall survival increased up to 43% 
(Cheng et al., 1999). However, data on long-term local control appear still disappointing 
especially in comparison with the results of wide radical resection. 
It is to note that two authors (Cheng, 1999, Baratti, 2003) pointed out no significant 
differences in terms of local control and overall survival comparing patients with positive 
margins treated with adjuvant radiotherapy with those having negative margins who did 
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Author 
N. Irr. 
Pts 
Site Surg. 
Dose in CGE
Mean/Range
Results (%)
Med F/U 
in months 
(range) 
Nowakowsky
et al. 
12 12 SP NR 
He-Ne +/- Ph
72/-
3y LC 33
3y OS 48
28 
(18-89) 
Schoenthaler 
et al. 
14 14 S 
4 MT, 8 
ST, 
2 B 
He +/- Ne-
Ph 
75/70-80 
LC
5y 55 
10y 23 
OS 
5y 85 
10y 22
Mean 65 
(22-164) 
Breteau 
et al. 
12 11 S Cx 
2 B; 
10 ID 
N + Ph
-/55-65 
N only 
-/10 and 17.6
4y LC 54 
4y OS 61 
NR 
Munzenrider & 
Liebsch 
85 85 SP NR 
Ph + P 
-/66-83 
LC
5y 69 
10y 48 
OS 
5y 80 
10y 33
36 
(1-172) 
Hug 
et al. 
14 8 S, 6 SP
4 MT, 8 
ST, 
2 B
Ph + P 
75/67-82 
5y LC 53 
5y OS 50 
Mean 38 
(6-136) 
Schulz-Ertner
et al. 
16 8 S, 8 SP NR 
C +/- Ph
Ovrl med 68
Ab. LC 87
Ab. OS 87
NR 
Park 
et al. 
27 27 S 
5 NM, 
16 PM, 
6 B/ID 
Ph +/- P 
72/59-84 
LC
5y 72 
10y 57 
OS 
5y 82 
10y 62
Mean 91 
(26-261) 
Rutz 
et al. 
26 
7 S-Cx, 19 
SP 
18 MT, 
8 ST 
P +/- Ph 
-/59-74 
LC
3y 86 
5y 69 
OS 
3y 84
35 
(13-72) 
Wagner 
et al. 
25 25 S-SP NR 
P, Ph, P + Ph
-/70-77
5y LC 73
5y OS 64
32 
Imai 
et al. 
95 95 S 95 ID 
70/53-74
(70 CGE in 
90% of pts)
5y LC 88 
5y OS 86 
NR 
Legend: N.: number; irr.: irradiated; pts: patients; surg.: surgery; CGE: Cobalt Gray equivalent; S: sacral; 
SP: spinal; Cx: coccygeal; NR: not reported; MT: macroscopically total resection; ST: subtotal resection; 
B: biopsy; ID: inoperable disease but pathologically proved; NM: negative margins; PM: positive 
margins; He: helium ions; Ne: neon ions; Ph: photons; N: neutrons; P: protons; C: carbon ions; ovrl: 
overall; y: year; LC: local control; OS: overall survival; ab.: absolute.  
Table 7. Main series concerning vertebral chordomas treated with particle radiotherapy 
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not receive adjuvant irradiation. Finally, the only series reporting the use of intensity-
modulated radiation therapy (Zabel-du Bois et al., 2010) highlighted that dose higher than 
60 Gy significantly improved local control and overall survival as well as the radiation 
delivery at the time of initial diagnosis. The disappointing local control rate reported in this 
study could be explained considering the wide range of dose delivered to the gross tumor 
volume with only a limited number of patients receiving 72 Gy. 
The significant advantage related to the different energy deposition in tissues supported the 
use of charged particles (protons, ions, neutrons) also in spinal chordomas. As above 
mentioned, protons do not have a significant biologic advantage over conventional photon 
irradiation and only their physical properties make attractive this treatment modality. 
Conversely, concerning ions, the favorable physical features coexist with a radiobiological 
advantage that could further increase the tumor control probability. 
Such evolutionary technique has been applied to vertebral chordomas only recently. 
Therefore, only a limited number of studies are reported in literature (main series are 
summarized in Table 7).  
Likewise to photon radiotherapy, mainly mono-institutional retrospective series enrolling a 
limited number of patients over many years are reported. However, most series employing 
particle radiotherapy were able to deliver average doses exceeding 70 Gy as well as total 
doses even higher than 80 Gy. 
Therefore, analyzing the results, it is not surprising that they are generally better than those 
registered in photon radiotherapy series. The 5-year local control ranged between 53% (Hug 
et al., 1995) and 72% (Park et al., 2006) in the studies employing protons and between 55% 
(Schoenthaler et al., 1993) and 88% (Imai et al., 2011) in those using ions. The corresponding 
5-year overall survival rates varied between 50% (Hug et al., 1995) and 82% (Park et al., 
2006) in the proton series and between 85% (Schoenthaler et al., 1993) and 88% (Imai, 2011) 
in studies using ions. Disappointing results were reported only in one study (Nowakowsky 
et al., 1992). Almost all these series have not enough long follow-up. Hence, it is fair 
wondering whether such results are long lasting. With this regard data are not consistent 
and actuarial 10-year local control varied between 23% (Schoenthaler et al., 1993) and 57% 
(Park et al., 2006). Concerning overall survival, the actuarial rate at 10 years ranged between 
22% (Schoenthaler et al., 1993) and 62% (Park et al., 2006). However, if the best results will 
be confirmed at adequate follow-up they will be consistent with data reported in patients 
treated by wide radical resection. This scenario could offer a new standard of care: a 
function-preserving surgery followed by high-dose radiotherapy (particle or mixed 
particle/photon). It is worth of note that results pointed out by Imai et al. (Imai et al., 2011) 
concern only inoperable patients even suggesting the possibility to avoid surgery. Finally, 
three authors (Nowakowsky, 1992, Schoenthaler, 1993, Park, 2006) pointed out the 
improvement of local control delivering the irradiation at the time of initial diagnosis. 
In summary, radical tumor resection with adequate margins can achieve optimal results in 
terms of local control and overall survival even though at the expense of relevant peri-
operative morbidity suggesting that such surgical procedures could be reserved for patients 
with a high cure possibility. The functional consequences should be clearly discussed 
preoperatively with the patient as well as the nature of the disease. 
Radiation therapy, when positive surgical margin or residual tumor is present can improve 
the local control. Long lasting results in terms of local control can be achieved only 
delivering doses higher than 70 Gy. Such a strategy could also translate in high long-term 
overall survival rates. In order to optimize the outcome, adjuvant radiotherapy should be 
applied preferably at the time of initial diagnosis rather than at relapse. 
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Similar to skull base chordomas management, a function-preserving surgery followed by 
high-dose radiotherapy could represent a new standard of care. 
4. Conclusion 
Chordomas are rare primary bone tumors with a high risk for local recurrence and modest 
propensity for distant metastasis. Optimal therapy of chordoma is a combined approach of 
maximal safe surgical resection followed by proton beam irradiation for residual disease. 
In our review, radiation therapy demonstrated to be a valuable modality for the 
achievement of durable local control in the postoperative setting, particularly with the 
advent of charged particle radiotherapy. The use of protons has shown better results in 
comparison to the use of conventional photon irradiation, with favourable long-term 
outcome and relatively few significant complications considering the high doses delivered. 
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